Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVP-1012 in Early Parkinson's Disease
NCT02337725Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing TVP-1012 1 mg with Placebo (2 arms). Primary endpoint: Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III Total Score at 26 weeks. Started Feb 2015; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02337725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337725.